GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (FRA:LP6) » Definitions » EBIT

Livzon Pharmaceutical Group (FRA:LP6) EBIT : €359 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Livzon Pharmaceutical Group EBIT?

Livzon Pharmaceutical Group's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €91 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €359 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Livzon Pharmaceutical Group's annualized ROC % for the quarter that ended in Sep. 2024 was 21.09%. Livzon Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 62.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Livzon Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 11.07%.


Livzon Pharmaceutical Group EBIT Historical Data

The historical data trend for Livzon Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Livzon Pharmaceutical Group EBIT Chart

Livzon Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.61 316.11 323.71 328.78 319.11

Livzon Pharmaceutical Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.53 56.50 110.79 100.83 91.23

Competitive Comparison of Livzon Pharmaceutical Group's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Livzon Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Livzon Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Livzon Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Livzon Pharmaceutical Group's EV-to-EBIT falls into.



Livzon Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €359 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Livzon Pharmaceutical Group  (FRA:LP6) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Livzon Pharmaceutical Group's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=372.652 * ( 1 - 14.87% )/( (1471.146 + 1536.669)/ 2 )
=317.2386476/1503.9075
=21.09 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3275.127 - 803.934 - ( 1481.119 - max(0, 1241.783 - 2241.83+1481.119))
=1471.146

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3171.748 - 667.34 - ( 1376.35 - max(0, 1147.675 - 2115.414+1376.35))
=1536.669

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Livzon Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=364.92/( ( (586.583 + max(-240.327, 0)) + (587.94 + max(-109.081, 0)) )/ 2 )
=364.92/( ( 586.583 + 587.94 )/ 2 )
=364.92/587.2615
=62.14 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(300.645 + 252.73 + 23.392) - (803.934 + 0 + 13.16)
=-240.327

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(273.359 + 253.317 + 43.119) - (667.34 + 0 + 11.536)
=-109.081

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Livzon Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=359.356/3247.006
=11.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Livzon Pharmaceutical Group EBIT Related Terms

Thank you for viewing the detailed overview of Livzon Pharmaceutical Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Livzon Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.

Livzon Pharmaceutical Group Headlines

No Headlines